These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21545271

  • 1. Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium.
    Antoine C, Ameye L, Moreau M, Paesmans M, Rozenberg S.
    Climacteric; 2011 Aug; 14(4):464-71. PubMed ID: 21545271
    [Abstract] [Full Text] [Related]

  • 2. Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium.
    Antoine C, Ameye L, Paesmans M, Rozenberg S.
    Maturitas; 2012 Aug; 72(4):317-23. PubMed ID: 22627077
    [Abstract] [Full Text] [Related]

  • 3. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg.
    Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, Van Leeuwen FE, Buntinx F.
    Breast Cancer Res Treat; 2009 Nov; 118(2):425-32. PubMed ID: 19238536
    [Abstract] [Full Text] [Related]

  • 4. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [Abstract] [Full Text] [Related]

  • 5. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years.
    Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson I, Ahlgren J, Bergkvist L.
    Breast Cancer Res Treat; 2010 Jun; 121(3):679-83. PubMed ID: 19894110
    [Abstract] [Full Text] [Related]

  • 6. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M, Koera K, Nagata H, Nakano H.
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [Abstract] [Full Text] [Related]

  • 7. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR, Gadducci A, Gambacciani M.
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [Abstract] [Full Text] [Related]

  • 8. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence.
    Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M.
    Maturitas; 2009 Oct 20; 64(2):80-5. PubMed ID: 19709827
    [Abstract] [Full Text] [Related]

  • 9. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy.
    Katalinic A, Rawal R.
    Breast Cancer Res Treat; 2008 Feb 20; 107(3):427-30. PubMed ID: 17453336
    [Abstract] [Full Text] [Related]

  • 10. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
    Tzingounis V, Cardamakis E, Ginopoulos P, Argiropoulos G.
    Anticancer Res; 1996 Feb 20; 16(6C):3997-4000. PubMed ID: 9042326
    [Abstract] [Full Text] [Related]

  • 11. [Estrogen replacement therapy and breast cancer].
    Bakken K, Alsaker E, Eggen AE, Lund E.
    Tidsskr Nor Laegeforen; 2005 Feb 03; 125(3):282-5. PubMed ID: 15702147
    [Abstract] [Full Text] [Related]

  • 12. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase.
    Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P.
    Gynecol Endocrinol; 2007 Jul 03; 23(7):391-7. PubMed ID: 17701770
    [Abstract] [Full Text] [Related]

  • 13. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva.
    Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, Schaffar R, Vlastos G, Wespi Y, Schäfer P, Rapiti E.
    Breast Cancer Res Treat; 2010 Apr 03; 120(2):519-23. PubMed ID: 19633953
    [Abstract] [Full Text] [Related]

  • 14. Use of HRT and the subsequent risk of cancer.
    Beral V, Banks E, Reeves G, Appleby P.
    J Epidemiol Biostat; 1999 Apr 03; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
    [Abstract] [Full Text] [Related]

  • 15. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy.
    Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P.
    Ann Oncol; 2010 Dec 03; 21(12):2356-2360. PubMed ID: 20439342
    [Abstract] [Full Text] [Related]

  • 16. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
    Olsson HL, Ingvar C, Bladström A.
    Cancer; 2003 Mar 15; 97(6):1387-92. PubMed ID: 12627501
    [Abstract] [Full Text] [Related]

  • 17. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries.
    Zbuk K, Anand SS.
    J Epidemiol Community Health; 2012 Jan 15; 66(1):1-7. PubMed ID: 21875869
    [Abstract] [Full Text] [Related]

  • 18. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C, Pedersen AT, Lynge E, Ottesen B.
    Acta Obstet Gynecol Scand; 2003 Apr 15; 82(4):335-44. PubMed ID: 12716318
    [Abstract] [Full Text] [Related]

  • 19. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE.
    Acta Endocrinol (Copenh); 1991 Apr 15; 125 Suppl 1():13-26. PubMed ID: 1801500
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.